Eur Rev Med Pharmacol Sci 2018; 22 (17): 5747-5754

DOI: 10.26355/eurrev_201809_15843

Childhood multiple sclerosis: clinical features and recent developments on treatment choices and outcomes

Q. An, C.-H. Fan, S.-M. Xu

Department of Internal Medicine, Xuzhou Children’s Hospital, Xuzhou, Jiangsu, P.R. China. fanconghai020@163.com


Multiple sclerosis (MS) is an inflammatory idiopathic autoimmune disease causing demyelination of central nervous system (CNS). The incidence of pediatric MS is relatively rare, affecting 0.2 to 0.64/100,000 subjects; cases with MS onset before age 10-12 years, account for less than 1% of all MS cases, while 2.7 to 10.5% of all MS cases worldwide are seen in children <18 years of age, with a strong female preponderance. The disease course of MS varies from a benign type with relatively low level of disability after a long duration (15 years) of the disease, to a malignant type of MS with severe disability or even death within few months following onset. Diagnostic criteria for pediatric MS include ≥ 2 clinical events involving more areas of CNS inflammation in the absence of encephalopathy, separated by > 30 days, along with the involvement of brainstem. Pediatric MS generally presents relapsing-remittent form of MS, with majority of the patients recovering from the first attack. Major histocompatibility complex, more specifically, mutations in the human leukocyte antigen (HLA) DRB1*15 allele, are considered most important genetic factors that are contributory to the disease. Treatment choices for pediatric MS include many disease-modifying therapies (DMT) that are currently being used for adult MS and these are interferon-β 1a/1b (IFN-β1a/1b), glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, etc. However, most of these have not gone through complete testing in randomized, placebo-controlled clinical trials for pediatric MS and are being prescribed off-label by clinicians. As these studies are progressing, it is important to address if these approaches of treating pediatric MS patients have any long-term impact on patients, in particular, physical, cognitive, developmental and social outcomes of the children.

Free PDF Download

To cite this article

Q. An, C.-H. Fan, S.-M. Xu
Childhood multiple sclerosis: clinical features and recent developments on treatment choices and outcomes

Eur Rev Med Pharmacol Sci
Year: 2018
Vol. 22 - N. 17
Pages: 5747-5754
DOI: 10.26355/eurrev_201809_15843